Stock AnalizPfizer (PFE) earnings for the quarter ended September 2026: EPS beats estimates
Pfizer reported results for the quarter ended September 2026 on November 3, 2026. Adjusted earnings per share came in at $0.87 against the analysts’ average forecast of $0.74, a beat of 18.3%.
Revenue for the quarter was $16.58 billion, down 0.4% from $16.65 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 0.4% on the first trading day after the report.
The last four quarters
Pfizer has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.87 | $0.74 | +18.3% | −0% | +0.4% |
| Jun 2026 | $0.77 | $0.68 | +12.9% | +3% | +3.1% |
| Mar 2026 | $0.75 | $0.72 | +3.9% | +5% | +0.9% |
| Dec 2025 | $0.66 | $0.57 | +16.2% | −1% | +0.4% |
What comes next
Analysts expect EPS of $0.69 for the next quarter on average and $3.05 for the fiscal year ending December 31, 2026.
The average analyst price target is $30.22, 5% above the current price of $28.89.
Valuation and score
Pfizer scores 2.2 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 41.3, and its intrinsic value under moderate assumptions is about 30% below the current market value. Full Pfizer analysis with 10 years of financials
Frequently asked questions
What was Pfizer’s EPS for the quarter ended September 2026?
$0.87 adjusted per share, against an analyst consensus of $0.74.
How much revenue did Pfizer report?
$16.58 billion, down 0.4% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.